Scientific article
Open access

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

Published inThe New England journal of medicine, vol. 366, no. 14, p. 1287-1297
Publication date2012

A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism.

  • Administration
  • Oral
  • Aged
  • Anticoagulants/adverse effects/therapeutic use
  • Drug Therapy
  • Combination
  • Enoxaparin/adverse effects/therapeutic use
  • Female
  • Follow-Up Studies
  • Hemorrhage/chemically induced
  • Humans
  • International Normalized Ratio
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Morpholines/adverse effects/therapeutic use
  • Pulmonary Embolism/drug therapy/mortality
  • Recurrence
  • Thiophenes/adverse effects/therapeutic use
  • Treatment Outcome
  • Vitamin K/antagonists & inhibitors
Citation (ISO format)
BÜLLER, Harry R et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. In: The New England journal of medicine, 2012, vol. 366, n° 14, p. 1287–1297. doi: 10.1056/NEJMoa1113572
Main files (1)
Article (Published version)
ISSN of the journal0028-4793

Technical informations

Creation10/11/2012 9:59:00 AM
First validation10/11/2012 9:59:00 AM
Update time03/14/2023 8:02:28 PM
Status update03/14/2023 8:02:27 PM
Last indexation01/16/2024 1:11:06 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack